Compare Prudential Financial Inc (PRU) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential Financial Inc vs Sana Biotechnology Inc — how do they compare? Prudential Financial Inc trades at $113.2 (market cap $39.17B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Prudential Financial Inc is far larger — about 46.8× Sana Biotechnology Inc's market cap, and Prudential Financial Inc pays a 4.93% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential Financial Inc for 145 Days and Sana Biotechnology Inc for 23 Days on average.
| PRU | SANA | |
|---|---|---|
Market Cap | $39.17B | $836.71M |
Volume | 1,436,917 | 4,507,444 |
Sector | Financials | Health |
52-Week High | $125.13 | $5.92 |
52-Week Low | $92.00 | $2.68 |
Typical Hold Time | 145 Days | 23 Days |
Enterprise Value | $67.95B | $749.96M |
Dividend Yield | 4.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential Financial (PRU) trades at $113.09, up 0.65% with bearish technical signals but attractive valuation metrics including a P/E of 10.29 and P/S of 0.61. Recent earnings show mixed results with Q1 and Q2 2026 beats but a Q4 2025 miss. The company is executing a strategic overhaul including $3 billion capital rotation and $750 million cost savings while exiting emerging markets through the $185 million Alexforbes sale. Cash flow trends show strong operational performance with $6.3 billion from operations in 2025.
PRU presents a value opportunity with below-market valuations and dividend yield support, though technical weakness and mixed analyst sentiment warrant caution. The strategic refocus on core insurance and wealth management businesses positions the company for improved capital efficiency, while higher interest rates benefit investment income. Key risks include execution challenges in the restructuring and competitive pressures in the insurance sector.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
